Clinical Trial Search
Malignant Melanoma
-
GO28394
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma Not yet recruiting -
GO28396
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients with BRAFV600 Mutation-Positive Metastatic Malignancies Not yet recruiting -
GO28398
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy Not yet recruiting -
GO27826
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma Recruiting -
GO27935
A Study of DEDN6526A in Patients with Metastatic or Unresectable Melanoma Recruiting -
GO28052
A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy Recruiting -
GO28054
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma Recruiting -
GO28141
A Phase 3 study comparing GDC-0973, a MEK inhibitor, in combination with Vemurafenib vs Vemurafenib alone in patients with Metastatic Melanoma Recruiting -
GO28397
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy Recruiting -
GP28384
A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients with Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma Recruiting -
ML27763
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E Recruiting -
ML28471
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples Recruiting -
ML28579
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics Recruiting -
MO25515
A Study of RO5185426 in Patients With Metastatic Melanoma Recruiting -
MO25743
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases Recruiting -
NO25390
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Recruiting -
NO25395
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma Recruiting -
ML18727
A Study of Avastin (Bevacizumab) in Combination With Dacarbazine in Patients With Unresectable/Metastatic Melanoma. Completed -
ML19309
A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma Completed -
ML25597
A Study of RO5185426 in Patients With Metastatic Melanoma Completed -
MO25653
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases Completed -
NO16007
A Study to Optimize the Dose of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Metastatic Malignant Melanoma Completed -
NP25158
A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma Completed -
NO25026
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) Active, not recruiting -
NP22657
A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma Active, not recruiting -
NP22676
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma Active, not recruiting -
NP25163
A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma Active, not recruiting -
NP25247
A Study of RO5212054 (PLX3603) in Patients With BRAF V600-mutated Advanced Solid Tumours Active, not recruiting -
NP25396
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma Active, not recruiting